PharmacyCodes



Quinaglute Dura-Tabs en es it fr

Categoria

Quinaglute Dura-Tabs Marchi, Quinaglute Dura-Tabs Analoghi

Quinaglute Dura-Tabs Marchi miscela

  • No information avaliable

    • Quinaglute Dura-Tabs Formula chimica

    C20H24N2O2

    Quinaglute Dura-Tabs RX link

    http://www.rxlist.com/cgi/generic/quinidine.htm

    Quinaglute Dura-Tabs FDA foglio

    Quinaglute_Dura-Tabs FDA

    Quinaglute Dura-Tabs DMS (foglio di materiale di sicurezza)

    Quinaglute Dura-Tabs Sintesi di riferimento

    Nessuna informazione disponibile

    Quinaglute Dura-Tabs Peso molecolare

    324.417 g/mol

    Quinaglute Dura-Tabs Temperatura di fusione

    174 oC

    Quinaglute Dura-Tabs H2O Solubilita

    140 mg / L

    Quinaglute Dura-Tabs Stato

    Solid

    Quinaglute Dura-Tabs LogP

    2.534

    Quinaglute Dura-Tabs Forme di dosaggio

    Soluzione

    Quinaglute Dura-Tabs Indicazione

    Per il trattamento di pre-eccitazione ventricolare e aritmie cardiache

    Quinaglute Dura-Tabs Farmacologia

    Chinidina, un anticonvulsivo idantoina, รจ usato da solo o con anticonvulsivanti fenobarbital o altro per gestire crisi tonico-cloniche, crisi psicomotoria, sindromi da dolore neuropatico diabetico compresi neuropatia, aritmie cardiache indotte da digitale, e aritmie cardiache associate a prolungamento dell'intervallo QT.

    Quinaglute Dura-Tabs Assorbimento

    Nessuna informazione disponibile

    Quinaglute Dura-Tabs Tossicita

    Nessuna informazione disponibile

    Quinaglute Dura-Tabs Informazioni paziente

    Before prescribing QUINAGLUTE® as prophylaxis against recurrence of atrial fibrillation, the physician should inform the patient of the risks and benefits to be expected. Discussion should include the facts

    • that the goal of therapy will be a reduction (probably not to zero) in the frequency of episodes of atrial fibrillation; and
    • that reduced frequency of fibrillatory episodes may be expected, if achieved, to bring symptomatic benefit; but
    • that no data are available to show that reduced frequency of fibrillatory episodes will reduce the risks of irreversible harm through stroke or death; and in fact
    • that such data as are available suggest that treatment with QUINAGLUTE® is likely to increase the patient's risk of death.

    To confirm whether this is the most current prescribing information available on Quinaglute®, or to obtain the most current prescribing information, please call Berlex Laboratories at 1-888-BERLEX-4 (choose option #4, Product Usage Information).

    Quinaglute Dura-Tabs Atto interessato organismi

    Gli esseri umani e altri mammiferi